Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer: New Insights From External Independent Validation.

Cicchetti A, Avuzzi B, Palorini F, Ballarini F, Stucchi C, Fellin G, Gabriele P, Vavassori V, Esposti CD, Cozzarini C, Fiorino C, Rancati T, Valdagni R.

Int J Radiat Oncol Biol Phys. 2018 Jun 30. pii: S0360-3016(18)30806-X. doi: 10.1016/j.ijrobp.2018.05.013. [Epub ahead of print]

PMID:
29970313
2.

Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients: Results from a large pooled population.

Cicchetti A, Rancati T, Ebert M, Fiorino C, Palorini F, Kennedy A, Joseph DJ, Denham JW, Vavassori V, Fellin G, Avuzzi B, Stucchi C, Valdagni R.

Phys Med. 2016 Dec;32(12):1690-1697. doi: 10.1016/j.ejmp.2016.09.018. Epub 2016 Oct 6.

PMID:
27720692
3.

Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials.

Caffo O, Thompson C, De Santis M, Kragelj B, Hamstra DA, Azria D, Fellin G, Pappagallo GL, Galligioni E, Choudhury A.

Radiother Oncol. 2016 Nov;121(2):193-198. doi: 10.1016/j.radonc.2016.09.006. Epub 2016 Oct 5.

PMID:
27720221
4.

Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.

Fellin G, Mirri MA, Santoro L, Jereczek-Fossa BA, Divan C, Mussari S, Ziglio F, La Face B, Barbera F, Buglione M, Bandera L, Ghedi B, Di Muzio NG, Losa A, Mangili P, Nava L, Chiarlone R, Ciscognetti N, Gastaldi E, Cattani F, Spoto R, Vavassori A, Giglioli FR, Guarneri A, Cerboneschi V, Mignogna M, Paoluzzi M, Ravaglia V, Chiumento C, Clemente S, Fusco V, Santini R, Stefanacci M, Mangiacotti FP, Martini M, Palloni T, Schinaia G, Lazzari G, Silvano G, Magrini S, Ricardi U, Santoni R, Orecchia R.

Br J Radiol. 2016 Sep;89(1065):20150981. doi: 10.1259/bjr.20150981. Epub 2016 Jul 7.

5.

Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study.

Veccia A, Caffo O, Fellin G, Mussari S, Ziglio F, Maines F, Tomio L, Galligioni E.

Radiat Oncol. 2015 Jun 10;10:130. doi: 10.1186/s13014-015-0434-4.

6.

Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding phase 2 study.

Maggio A, Magli A, Rancati T, Fiorino C, Valvo F, Fellin G, Ricardi U, Munoz F, Cosentino D, Cazzaniga LF, Valdagni R, Vavassori V.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):518-24. doi: 10.1016/j.ijrobp.2014.03.018. Epub 2014 May 3.

PMID:
24803033
7.

Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.

Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, Mazzoleni G, Dalla Palma P, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):594-600. doi: 10.1158/1055-9965.EPI-13-1180. Epub 2014 Feb 10.

8.

Long term rectal function after high-dose prostatecancer radiotherapy: results from a prospective cohort study.

Fellin G, Rancati T, Fiorino C, Vavassori V, Antognoni P, Baccolini M, Bianchi C, Cagna E, Borca VC, Girelli G, Iacopino B, Maliverni G, Mauro FA, Menegotti L, Monti AF, Romani F, Stasi M, Valdagni R.

Radiother Oncol. 2014 Feb;110(2):272-7. doi: 10.1016/j.radonc.2013.09.028. Epub 2013 Dec 11.

PMID:
24332020
9.

Frequency of brain metastases from prostate cancer: an 18-year single-institution experience.

Caffo O, Veccia A, Fellin G, Mussari S, Russo L, Tomio L, Galligioni E.

J Neurooncol. 2013 Jan;111(2):163-7. doi: 10.1007/s11060-012-0994-1. Epub 2012 Oct 25.

PMID:
23096134
10.

Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature.

Caffo O, Veccia A, Fellin G, Russo L, Mussari S, Galligioni E.

Crit Rev Oncol Hematol. 2013 May;86(2):176-90. doi: 10.1016/j.critrevonc.2012.09.011. Epub 2012 Oct 22. Review.

PMID:
23088957
11.

Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial.

Valdagni R, Vavassori V, Rancati T, Fellin G, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Fiorino C.

Radiother Oncol. 2012 May;103(2):252-5. doi: 10.1016/j.radonc.2012.03.012. Epub 2012 Apr 20.

PMID:
22521747
12.

Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model.

Tomatis S, Rancati T, Fiorino C, Vavassori V, Fellin G, Cagna E, Mauro FA, Girelli G, Monti A, Baccolini M, Naldi G, Bianchi C, Menegotti L, Pasquino M, Stasi M, Valdagni R.

Phys Med Biol. 2012 Mar 7;57(5):1399-412. doi: 10.1088/0031-9155/57/5/1399. Epub 2012 Feb 21.

PMID:
22349550
13.

Late fecal incontinence after high-dose radiotherapy for prostate cancer: better prediction using longitudinal definitions.

Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, Valdagni R.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):38-45. doi: 10.1016/j.ijrobp.2011.06.1953. Epub 2011 Oct 8.

PMID:
21985939
14.

Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning.

Perna L, Cozzarini C, Maggiulli E, Fellin G, Rancati T, Valdagni R, Vavassori V, Villa S, Fiorino C.

Radiat Oncol. 2011 Sep 24;6:123. doi: 10.1186/1748-717X-6-123.

15.

Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer.

Rancati T, Fiorino C, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, Valdagni R.

Radiother Oncol. 2011 Jul;100(1):124-30. doi: 10.1016/j.radonc.2011.06.032. Epub 2011 Jul 7.

PMID:
21741721
16.

Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome.

Valdagni R, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G, Cagna E, Gabriele P, Mauro FA, Baccolini M, Bianchi C, Menegotti L, Monti AF, Stasi M, Giganti MO, Fiorino C.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1957-66. doi: 10.1016/j.ijrobp.2011.03.028. Epub 2011 Jun 2.

PMID:
21640511
17.

Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies.

Caffo O, Fellin G, Graffer U, Mussari S, Tomio L, Galligioni E.

Cancer. 2011 Mar 15;117(6):1190-6. doi: 10.1002/cncr.25667. Epub 2010 Oct 19.

18.
19.

Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study.

Fellin G, Fiorino C, Rancati T, Vavassori V, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Valdagni R.

Radiother Oncol. 2009 Nov;93(2):197-202. doi: 10.1016/j.radonc.2009.09.004. Epub 2009 Oct 12.

PMID:
19828205
20.

To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy.

Valdagni R, Rancati T, Ghilotti M, Cozzarini C, Vavassori V, Fellin G, Fiorino C, Girelli G, Barra S, Zaffaroni N, Pierotti MA, Gariboldi M.

Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1431-40. doi: 10.1016/j.ijrobp.2008.10.021. Epub 2009 Feb 11.

PMID:
19211196
21.

Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT.

Valdagni R, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M, Bianchi C, Cagna E, Greco C, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Vavassori V.

Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1065-73. doi: 10.1016/j.ijrobp.2007.11.037. Epub 2008 Jan 30.

PMID:
18234449
22.

Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study.

Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, Girelli G, Mapelli M, Menegotti L, Nava S, Valdagni R.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1130-7. Epub 2007 Sep 19.

PMID:
17881142
23.

Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.

Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, Bianchi C, Cagna E, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Valdagni R.

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1401-10. Epub 2007 Jan 22.

PMID:
17241754
24.

Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer.

Caffo O, Fellin G, Bolner A, Coccarelli F, Divan C, Frisinghelli M, Mussari S, Ziglio F, Malossini G, Tomio L, Galligioni E.

Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):31-7. Epub 2006 Jun 9.

PMID:
16765529
25.

Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101).

Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, Cozzarini C, Fellin G, Foppiano F, Girelli G, Menegotti L, Piazzolla A, Vavassori V, Valdagni R.

Radiother Oncol. 2004 Oct;73(1):21-32.

PMID:
15465142
26.

Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.

Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, Tomio L, Galligioni E.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1310-6.

PMID:
14630267
27.

Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer.

Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, Piazzolla A, Vavassori V, Valdagni R.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):953-62.

PMID:
14575825
28.

The role of brachytherapy in the management of oropharyngeal carcinomas: the Trento experience.

Bolner A, Mussari S, Fellin G, Pani G, Busana L, Caffo O, Tomio L.

Tumori. 2002 Mar-Apr;88(2):137-41.

PMID:
12088254
29.

[Brachytherapy in the management of the initial stage of the mobile tongue carcinoma].

Bolner A, Campolongo F, Segatta P, Fellin G, Bauer M, Nocini PF.

Acta Otorhinolaryngol Ital. 1999 Apr;19(2):80-6. Italian.

PMID:
10434439
30.

A European version of the Appropriateness Evaluation Protocol. Goals and presentation. The BIOMED I Group on Appropriateness of Hospital Use.

Lang T, Liberati A, Tampieri A, Fellin G, Gonsalves Mda L, Lorenzo S, Pearson M, Beech R, Santos-Eggimann B.

Int J Technol Assess Health Care. 1999 Winter;15(1):185-97.

PMID:
10407605
31.

[Intraoperative radiotherapy in the combined treatment of pancreatic cancers].

Fellin G, Pani G, Tomio L, Tirone G, Eccher C.

Tumori. 1999 Jan-Feb;85(1 Suppl 1):S33-5. Review. Italian.

PMID:
10235078
32.

Comparison between two prospective studies of cardiovascular disease carried out amongst renal replacement patients in UK and Italy.

Brown JH, Fellin G, Hunt LP, Vites NP, D'Amico G, Mallick NP.

Nephrol Dial Transplant. 1998 Feb;13(2):449-52.

PMID:
9509461
33.

Hyperfractionated radiation in combination with local hyperthermia in the treatment of advanced squamous cell carcinoma of the head and neck: a phase I-II study.

Amichetti M, Romano M, Busana L, Bolner A, Fellin G, Pani G, Tomio L, Valdagni R.

Radiother Oncol. 1997 Nov;45(2):155-8.

PMID:
9424006
34.

Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.

Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L.

Br J Urol. 1997 Jul;80(1):44-9.

PMID:
9240179
35.

Assessment of quality of life after radical radiotherapy for prostate cancer.

Caffo O, Fellin G, Graffer U, Luciani L.

Br J Urol. 1996 Oct;78(4):557-63.

PMID:
8944512
36.

Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire.

Caffo O, Fellin G, Graffer U, Luciani L.

Cancer. 1996 Sep 1;78(5):1089-97. Erratum in: Cancer 1996 Nov 1;76(9):2037.

PMID:
8780548
37.

[Hyperthermia and palliative radiotherapy for sarcoma].

Amichetti M, Graiff C, Romano M, Bolner A, Busana L, Fellin G, Pani G, Valdagni R.

Radiol Med. 1996 Jun;91(6):796-8. Italian.

PMID:
8830368
38.

[Radiotherapy of T1N0 neoplasms of the glottis. Analysis of the parameters that influence local control].

Bolner A, Valentini A, Amichetti M, Busana L, Fellin G, Menegotti L, Nassivera E, Pani G, Romano M.

Radiol Med. 1995 Dec;90(6):804-7. Italian.

PMID:
8685467
39.

Appropriateness of hospital use: an overview of Italian studies.

Fellin G, Apolone G, Tampieri A, Bevilacqua L, Meregalli G, Minella C, Liberati A.

Int J Qual Health Care. 1995 Sep;7(3):219-25. Review.

PMID:
8595458
40.

Expression of mdm-2 and p53 protein in transitional cell carcinoma.

Barbareschi M, Girlando S, Fellin G, Graffer U, Luciani L, Dalla Palma P.

Urol Res. 1995;22(6):349-52.

PMID:
7537927
41.

Stage I seminoma of the testis: long term results and toxicity with adjuvant radiotherapy.

Amichetti M, Fellin G, Bolner A, Busana L, Pani G, Romano M, Scillieri M, Maluta S.

Tumori. 1994 Apr 30;80(2):141-5.

PMID:
8016907
42.

Critical re-evaluation of 41 cases of "idiopathic" crescentic glomerulonephritis.

Ferrario F, Tadros MT, Napodano P, Sinico RA, Fellin G, D'Amico G.

Clin Nephrol. 1994 Jan;41(1):1-9.

PMID:
8137564
43.

Effect of dietary protein restriction on the progression of renal failure: a prospective randomized trial.

D'Amico G, Gentile MG, Fellin G, Manna G, Cofano F.

Nephrol Dial Transplant. 1994;9(11):1590-4.

PMID:
7870348
44.

Treatment of proteinuric patients with a vegetarian soy diet and fish oil.

Gentile MG, Fellin G, Cofano F, Delle Fave A, Manna G, Ciceri R, Petrini C, Lavarda F, Pozzi F, D'Amico G.

Clin Nephrol. 1993 Dec;40(6):315-20.

PMID:
8299238
45.

Cisplatin, hyperthermia, and radiation (trimodal therapy) in patients with locally advanced head and neck tumors: a phase I-II study.

Amichetti M, Graiff C, Fellin G, Pani G, Bolner A, Maluta S, Valdagni R.

Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):801-7.

PMID:
8344849
46.

Typical and atypical natural history of IgA nephropathy in adult patients.

D'Amico G, Ragni A, Gandini E, Fellin G.

Contrib Nephrol. 1993;104:6-13. Review. No abstract available.

PMID:
8325035
47.

Rapidly progressive glomerulonephritis (RPGN): is there still an "idiopathic" subgroup?

Ferrario F, Tadros M, Napodano P, Giordano A, Sinico RA, Fellin G, D'Amico G.

Adv Exp Med Biol. 1993;336:431-4.

PMID:
8296650
48.

Small cell carcinoma of the urinary bladder. Report of two cases and review of the literature.

Amichetti M, Boi S, Fellin G, Maluta S, Dalla Palma P, Luciani L.

Tumori. 1992 Dec 31;78(6):409-13. Review.

PMID:
1338404
49.

Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome.

D'Amico G, Gentile MG, Manna G, Fellin G, Ciceri R, Cofano F, Petrini C, Lavarda F, Perolini S, Porrini M.

Lancet. 1992 May 9;339(8802):1131-4.

PMID:
1349366
50.

Undifferentiated small cell neuroendocrine carcinoma of the urinary bladder.

Amichetti M, Boi S, Fellin G, Dalla Palma P, Luciani L.

Eur J Cancer. 1992;28A(4-5):1004-5. No abstract available.

PMID:
1326303

Supplemental Content

Loading ...
Support Center